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background: Presence of Cheyne-Stokes respiration (CSR) in chronic heart failure (CHF) is associated with increased mortality. However, whether 
CSR is associated with worse prognosis because it reflects HF severity, or if pathophysiological characteristics of CSR independently affect survival, 
remains unclear. Thus, the aim of this study was to evaluate the prognostic effect of CSR compared to obstructive sleep apnea (OSA), in otherwise 
similar groups of CHF patients
Methods: During a period of median 46 weeks (904 to 2104 days), we followed 43 patients (4 women) with more than 25% CSR during sleeping 
time and 19 patients (2 women) with OSA and apnea-hypopnea index (AHI) ≥6. All included patients had CHF in New York Heart Association (NYHA) 
class II-IV despite optimal medication, and/or left ventricular ejection fraction (LVEF) ≤40%. Primary endpoint was mortality, and secondary endpoint 
was combined mortality and hospital readmission. All patents were on optimal heart failure medication, but no one was treated with any mechanical 
devices.
results: At baseline there were no statistical difference between the 2 groups regarding NYHA class 2.90.1 for the CSR group vs. 2.80.1 for the 
OSA group, LVEF 281 vs 302 % and body weight 82 (75-88) vs 85 (69-97) kg. The CSR group had higher age 702 vs. 633 years (p=0.012). The CSR 
group also had higher AHI 25 (10-43) vs. 11 (8-20). In the OSA group there were 5 (26%) deaths and 14 (74%) combined end-points. CSR patients 
had a significantly higher risk for both endpoints, experiencing 23 (53%) deaths (log rank p=0.040, HR 2.70 (1.01-7.22)) and 40 (93%) deaths or 
hospitalizations (log rank p=0.043, HR 1.96 (1.06-3.63))(Figure A-B). The association between CSR and death remained significant (p=0.026) even 
after adjusting for age, LVEF, NYHA class, body weight, AHI and heart failure medication in a Cox multivariate model.
conclusion: CSR is associated with higher mortality than the presence of OSA in CHF patients. These findings enhance the importance of effective 
treatment of CSR.
